Cargando…

Denileukin Diftitox in Combination with Rituximab for Previously Untreated Follicular B-cell Non-Hodgkin’s Lymphoma

Follicular lymphoma exhibits intratumoral infiltration by non-malignant T lymphocytes inluding CD4+CD25+ regulatory T (T(reg)) cells. We combined denileukin diftitox with rituximab in previously untreated, advanced-stage follicular lymphoma patients anticipating that denileukin diftitox would deplet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ansell, Stephen M., Tang, Hui, Kurtin, Paul J., Koenig, Patricia A., Nowakowski, Grzegorz S., Nikcevich, Daniel A., Nelson, Garth D., Yang, Zhizhang, Grote, Deanna M., Ziesmer, Steven C., Silberstein, Peter T., Erlichman, Charles, Witzig, Thomas E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3266999/ https://www.ncbi.nlm.nih.gov/pubmed/22015775 http://dx.doi.org/10.1038/leu.2011.297

Ejemplares similares

Denileukin diftitox for the treatment of cutaneous T-cell lymphoma
por: Kaminetzky, David, et al.
Publicado: (2008)

Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma
por: Lansigan, Frederick, et al.
Publicado: (2010)

Advanced-Stage Primary Cutaneous T-Cell Lymphoma Treated with Bexarotene and Denileukin Diftitox
por: Cervigón-González, Iván, et al.
Publicado: (2011)

Successful Treatment of Primary Cutaneous Anaplastic Large Cell Lymphoma with Denileukin Diftitox
por: Amagai, Mayuko, et al.
Publicado: (2022)

Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome
por: Prince, H. Miles, et al.
Publicado: (2013)

Denileukin Diftitox (Ontak) as Maintenance Therapy for Peripheral T-Cell Lymphomas: Three Cases with Sustained Remission
por: Fuentes, Alejandra C., et al.
Publicado: (2015)

Primary cutaneous anaplastic large-cell lymphoma: Complete remission for 13 years after denileukin diftitox
por: Lewis, Daniel J., et al.
Publicado: (2017)

Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma
por: Telang, Sucheta, et al.
Publicado: (2011)

Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial
por: Luke, Jason J., et al.
Publicado: (2016)

Soluble and Membrane-Bound TGF-β-Mediated Regulation of Intratumoral T Cell Differentiation and Function in B-Cell Non-Hodgkin Lymphoma
por: Yang, Zhi-Zhang, et al.
Publicado: (2013)

PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival
por: Yang, Z -Z, et al.
Publicado: (2015)

Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma
por: Spencer, Scott J, et al.
Publicado: (2021)

Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era
por: Arushi Khurana, et al.
Publicado: (2021)

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R(2)) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
por: Morschhauser, Franck, et al.
Publicado: (2022)

Rituximab maintenance in relapsed or refractory follicular non-Hodgkin’s lymphoma: the evidence of its therapeutic value
por: Ardeshna, Kirit M.
Publicado: (2007)

Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study
por: Desai, Sanjal H., et al.
Publicado: (2021)

Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma: A NICE Single Technology Appraisal
por: Greenhalgh, Janette, et al.
Publicado: (2013)

A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling
por: Hildebrand, Joanne M., et al.
Publicado: (2010)

Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective
por: Villasboas, Jose Caetano, et al.
Publicado: (2016)

Serum ferritin concentration in untreated Hodgkin's disease.
por: Jacobs, A., et al.
Publicado: (1976)

Maintenance rituximab in Veterans with follicular lymphoma
por: Halwani, Ahmad S., et al.
Publicado: (2020)

IL-10 induces the development of immunosuppressive CD14(+)HLA-DR(low/−) monocytes in B-cell non-Hodgkin lymphoma
por: Xiu, B, et al.
Publicado: (2015)

Rituximab in the treatment of non-Hodgkin’s lymphoma
por: Hauptrock, Beate, et al.
Publicado: (2008)

High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)
por: Witzig, T E, et al.
Publicado: (2017)

Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma
por: Davies, Andrew, et al.
Publicado: (2020)

Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma
por: Wang, Yucai, et al.
Publicado: (2018)

Imaging of Early Response to Predict Prognosis in the First-Line Management of Follicular Non-Hodgkin Lymphoma with Iodine-131-Rituximab Radioimmunotherapy
por: Kesavan, Murali, et al.
Publicado: (2017)

Rituximab induced hypoglycemia in non-Hodgkin's lymphoma
por: Hussain, Badrudeen M, et al.
Publicado: (2006)

Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up
por: Soini, E. J. O., et al.
Publicado: (2011)

Lymphocyte function in untreated Hodgkin's disease: an important predictor of prognosis.
por: Wedelin, C., et al.
Publicado: (1982)

Hodgkin Lymphoma Untreated for Six Years Presenting with Tracheoesophageal Fistula
por: Westin, Jason R., et al.
Publicado: (2012)

Rituximab maintenance therapy of follicular lymphoma in clinical practice
por: Dührsen, Ulrich, et al.
Publicado: (2018)

Expanded use of rituximab in the management of non-Hodgkin lymphoma
por: Eichenauer, Dennis A, et al.
Publicado: (2009)

Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance
por: Kim, Hee Kyung, et al.
Publicado: (2020)

Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate–High Risk: A Cost-Effectiveness Analysis
por: Bellone, Marco, et al.
Publicado: (2021)

P1092: A PHASE II INVESTIGATOR INITIATED STUDY OF ACALABRUTINIB, LENALIDOMIDE AND RITUXIMAB (AR2) IN PATIENTS WITH PREVIOUSLY UNTREATED HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA
por: Strati, Paolo, et al.
Publicado: (2023)

Composite follicular lymphoma and classic Hodgkin lymphoma
por: Kim, Han-Na, et al.
Publicado: (2022)

Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma
por: Grigg, Andrew, et al.
Publicado: (2017)

Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k9dumav04b1t7539f6unskirnr